RAC 4.32% $1.55 race oncology ltd

Ann: EMD AML MDS Trial Expands to Europe, page-95

  1. 2,572 Posts.
    lightbulb Created with Sketch. 396
    Agree with all points - we’re aren’t a ph3 drug in the 2 indications that hold most value though, and the time to prove these is still at large - leading to little buying pressure and therefore price failure.

    The coming update hopefully helps.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.